Is there still a place for malleable penile implants in the United States? Wilson’s Workshop

Author(s): Mohit Khera, John Mulcahy, Lexiaochuan Wen, Steven K. Wilson

JOURNAL

IJIR: Your Sexual Medicine Journal

YEAR

2020

DOI

https://doi.org/10.1038/s41443-020-00376-6

View on Publisher Site

Abstract Short Summary

This review discusses the continued role of malleable penile prostheses (MPP) in the U.S., highlighting patient groups who benefit from them. The study compares MPP with IPP and includes Rigicon’s Rigi10® among modern MPP options.

Abstract

Objective:

To explore the contemporary relevance and clinical indications for malleable penile implants in the United States.

Key Findings:

MPP devices offer clinical advantages in certain populations, such as those with poor manual dexterity, infection, priapism, or spinal cord injury. MPPs are associated with lower malfunction and revision rates than IPPs. Rigicon’s Rigi10® is introduced as a new MPP device with size variations, albeit without coatings.

Conclusion:

Despite the dominance of IPPs, MPPs remain a valuable option for select patient groups due to their simplicity, lower malfunction rates, and utility in salvage or complex cases. The market continues to evolve with new devices like Rigicon’s Rigi10^®

Clinical Relevance:

This study supports the continued use of MPPs in patients for whom IPPs may not be ideal, and highlights cost, infection risk, and anatomical considerations that favor MPPs in specific scenarios.

Keywords

Rigi10 malleable penile prosthesis erectile dysfunction salvage procedure priapism Peyronie’s disease spinal cord injury penile implant

This publication is available through the external link above. See the abstract for a summary of the research.

Back to Clinical Evidence